Approvals aren’t enough; Big Pharma R&D restructuring will continue

John Carroll Here's a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they ...

Bayer may hive off another unit as it doubles down on pharma, consumer health

Carly Helfand Turns out it may not be just Bayer's plastics business that's on its way out the door. The company is reportedly exploring a sale of its diabetes device business ...

New numbers back the meme: Pharma does spend more on marketing than R&D

Tracy Staton FiercePharma News

Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Emily Wasserman Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company has entered exclusive talks to acquire ...

Big Pharma backs EU antibiotic R&D plan, Pfizer prompts Karo cuts, Advent closes £146M fund

Nick Paul Taylor In this week's EuroBiotech Report, a who's who of Big Pharma companies joined a European public-private consortium to develop and test new economic models of ...

Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China

John Carroll Chris Liang had already forged a compelling profile in drug development when the newly formed Scripps Florida recruited him as head of chemistry back in 2004. Liang, who ...

Google taps Boston brains for EU VC unit, Big Pharma VCs back Forendo, Swiss IPO halted

Nick Paul Taylor In this week's EuroBiotech Report, Google revealed further details of its $ 100 million (€79 million) European venture capital unit, which is hunting for ...

Add Arbor Pharma to your shopping list: It’s on the block for $1B-plus

Carly Helfand It's a good time to be a specialty drugmaker–especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right ...

Report: Arbor Pharma goes on the block for $1B-plus

Damian Garde Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $ 1 billion. FierceBiotech ...

Catalyst Pharma to join parade of huge price hikes on old, cheap drugs

Tracy Staton Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand–and adding an enormous premium along the way. Once again, the cost increase ...

First-to-market launch? Bonus–but double bonus if you’re Big Pharma

Tracy Staton When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams ...

Are specialty pharma CEOs worth their salt?

Carly Helfand Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs? FiercePharma ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS